Results 81 to 90 of about 518 (147)

Additional file 11 of Marek’s disease vaccines-induced differential expression of known and novel microRNAs in primary lymphoid organ bursae of White Leghorn

open access: yes, 2020
Additional file 11: GO terms enriched by target genes of differentially expressed miRNAs in bursae between line 63and line 72birds 26 days post Rispens inoculation.
Mohammad Heidari (6617507)   +6 more
core   +1 more source

Multiplex quantitative real-time pcr developing rapid diagnostic kit for the detection of discrimination and marek's disease vaccine used in Turkey

open access: yes, 2019
Marek hastalığı evcil kanatlıların, periferal sinirlerinde demyelinizasyon, mononüklear infiltrasyonlarla kendini gösteren lenfoproliferatif ve oldukça kontagiyöz bir hastalığıdır. Marek, tüm kümes tavukçuluğu yapan ülkelerde bulunmaktadır.
Kardoğan, Özlem
core  

Telomerase activity and viral gene transcription : reliable criteria of vaccine protection in the case of Marek's disease

open access: yes, 2008
La maladie de Marek due à l’a-herpesvirus GaHV-2 (Gallid herpes virus) est un lymphome T du poulet contrôlable par vaccination. Nous avons recherché si l’activité télomérase et la transcription des gènes viraux étaient associées à la protection vaccinale.
Debba-Pavard, Manel
core  

A recombinant fowlpox virus vaccine expressing glycoprotein B gene from CVI988/Rispens strain of MDV: protection studies in different chickens.

open access: yesActa virologica, 2000
Recombinant fowlpox virus (rFPV) was constructed to express glycoprotein B (gB) gene from CVI988/Rispens strain of Marek's disease virus (MDV). The rFPV-gB/R alone and in combination with herpesvirus of turkey (HVT) preparations were evaluated for their protective efficacy against challenge with very virulent MDV strains Md5 and RB1B in different ...
X, Liu   +4 more
openaire   +1 more source

Immunization with the vAU5 mutant viruses protects chickens from lethal MDV infection.

open access: yes, 2013
A) MD-incidence in N2a (A; n = 14) and B) P2a (B; n = 14) chickens vaccinated with either vAU5, CVI988 or media alone (Mock) before challenge-infection with RB-1B. Precent protection from the onset of disease or being tumor-positive at termination of the
Keith W. Jarosinski (163234)   +4 more
core   +1 more source

Design of a recombinant vaccine against the Marek's disease from the populations dynamics analysis of variants population of the CV1988/rispens vaccine

open access: yes, 2013
Le Gallid herpesvirus 2 (GaHV-2), responsable de lymphomes T du poulet, est contrôlé par le vaccin CVI988/Rispens. Mes travaux de thèse ont montré que le vaccin était composé, au contraire des souches virulentes, d’une population dynamique de variants ...
Labaille, Jennifer
core  

Verifying the accuracy of dot-blot hybridization.

open access: yes, 2013
Lane M, DL 2000 DNA marker; lane 1 to 3, DNAs from spleens of the diseased broiler breeders; lane 4 and 5, DNAs from spleens of the 1 day old commercial chickens; lane 6, DNA from CEF inoculated with MD-CVI988/Rispens vaccine; lane 7, DNA from CEF ...
Shufen Zhu (311195)   +8 more
core   +1 more source

Effect of Widely Divergent Vaccination-Challenge Intervals on Protection Provided by Rispens CV1988 Vaccine Against Very Virulent Marek's Disease Virus Challenge in Isa Brown Chickens

open access: yes, 2014
Rispens CVI988 is a highly effective serotype 1 Marek's disease virus vaccine currently used to vaccinate layer and breeder chickens in Australia and worldwide. We tested the effects of Rispens CVI988 on the level of protection provided to commercial ISA
Islam, Tanzila   +3 more
core  

Home - About - Disclaimer - Privacy